Home Contact Sitemap

eRAM

encyclopedia of Rare Disease Annotation for Precision Medicine




Disease benign schwannoma
Comorbidity C0085113|neurofibromatosis
Sentences 24
PubMedID- 26377980 Strategy for the surgical treatment of vestibular schwannomas in patients with neurofibromatosis type 2.
PubMedID- 24718755 Audiovestibular characteristics of small cochleovestibular schwannomas in neurofibromatosis type 2.
PubMedID- 24393766 Two phase ii clinical trials (nct01207687, nct01125046) are assessing the effectiveness of bevacizumab in treating neurofibromatosis 2 patients with symptomatic vestibular schwannomas and recurrent or progressive meningiomas.
PubMedID- 22805104 Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
PubMedID- 24335931 Ipsilateral cochlear implantation after cochlear nerve preserving vestibular schwannoma surgery in patients with neurofibromatosis type 2.
PubMedID- 21817944 Objectives: to discuss our management strategy of vestibular schwannoma in patients with neurofibromatosis type 2 (nf2).
PubMedID- 22483820 The focus is on management of sporadic, unilateral vestibular schwannomas, because patients with neurofibromatosis type 2 pose different management problems best discussed separately.
PubMedID- 22681725 Additionally, this method of drug delivery may have important implications in the treatment of patients with vestibular schwannomas associated with neurofibromatosis type 2.
PubMedID- 24338149 Pediatric intramedullary schwannoma without neurofibromatosis is extremely rare with only five cases reported so far.
PubMedID- 20406973 Patients with bilateral vestibular schwannomas associated with neurofibromatosis type 2 (nf2) experience significant morbidity such as complete hearing loss.
PubMedID- 23225215 They are usually solitary and encapsulated masses, but multiple schwannomas may be associated with neurofibromatosis type 2. the tumour may grow through the adjacent intervertebral foramen and spinal canal to produce a “dumbbell” or “hourglass” configuration.
PubMedID- 23413263 Loss of the merlin tumour suppressor causes abnormal de-differentiation and proliferation of schwann cells and formation of schwannoma tumours in patients with neurofibromatosis type 2.
PubMedID- 22004800 Bevacizumab treatment for vestibular schwannomas in neurofibromatosis type two: report of two cases, including responses after prior gamma knife and vascular endothelial growth factor inhibition therapy.
PubMedID- 20150363 Bevacizumab induces regression of vestibular schwannomas in patients with neurofibromatosis type 2.
PubMedID- 23649401 schwannoma in neurofibromatosis type 1: a pitfall for detecting malignancy by metabolic imaging.
PubMedID- 26287269 Factors influencing the growth rate of vestibular schwannoma in patients with neurofibromatosis type 2.
PubMedID- 23453897 We present a case of macrodactyly of the small finger associated with a digital nerve plexiform schwannoma in a patient with neurofibromatosis type 2.
PubMedID- 23407292 Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results.
PubMedID- 23546912 Cerebral hernia caused by a thoracic surgery for multiple schwannomas in a patient with neurofibromatosis type 2.
PubMedID- 23351479 Although abnormal gag reflexes have been reported in cases of glossopharyngeal schwannoma and neurofibroma in patients with neurofibromatosis-1, a gag reflex has not been reported previously as a complication of im in the head and neck.
PubMedID- 26108240 Bevacizumab treatment for vestibular schwannoma in a patient with neurofibromatosis type 2: hearing improvement and tumor shrinkage.
PubMedID- 20736812 We sought to determine the activity of erlotinib for progressive vestibular schwannoma (vs) associated with neurofibromatosis 2 (nf2).
PubMedID- 21926040 Multiple cutaneous plexiform schwannomas revealing neurofibromatosis type 2 in a child - report of a novel mutation in this rare association.
PubMedID- 25362541 Vestibular schwannoma in a patient with neurofibromatosis type 1: clinical report and literature review.

Page: 1